Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 2, 6, 57, 23 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 12 and 7 molecules, respectively.
Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 13: Products under Development by Universities/Institutes, H2 2019
Table 14: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 15: Number of Products by Stage and Target, H2 2019
Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Mechanism of Action, H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Route of Administration, H2 2019
Table 20: Number of Products by Stage and Molecule Type, H2 2019
Table 21: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abhelix LLC, H2 2019
Table 22: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H2 2019
Table 23: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AIM ImmunoTech Inc, H2 2019
Table 24: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, H2 2019
Table 25: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes Inc, H2 2019
Table 26: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2019
Table 27: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AntoXa Corp, H2 2019
Table 28: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arisan Therapeutics Inc, H2 2019
Table 29: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Atreca Inc, H2 2019
Table 30: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Avipero Ltd, H2 2019
Table 31: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2019
Table 32: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Bharat Biotech Ltd, H2 2019
Table 33: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioComo Inc, H2 2019
Table 34: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Table 35: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, H2 2019
Table 36: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Biotron Ltd, H2 2019
Table 37: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Celdara Medical LLC, H2 2019
Table 38: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Chicago Biosolutions Inc, H2 2019
Table 39: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Cocrystal Pharma Inc, H2 2019
Table 40: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2019
Table 41: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2019
Table 42: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2019
Table 43: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergex Vaccines Ltd, H2 2019
Table 44: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2019
Table 45: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fab’entech SA, H2 2019
Table 46: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fibreu Ltd, H2 2019
Table 47: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2019
Table 48: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Galactica Biotech Ltd, H2 2019
Table 49: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, H2 2019
Table 50: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2019
Table 51: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gilead Sciences Inc, H2 2019
Table 52: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Global BioLife Inc Ltd, H2 2019
Table 53: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Greffex Inc, H2 2019
Table 54: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by H&P Labs Inc, H2 2019
Table 55: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Humabs BioMed SA, H2 2019
Table 56: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by IDBiologics Inc, H2 2019
Table 57: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ImmuneMed Inc, H2 2019
Table 58: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Immunomodulation Inc, H2 2019
Table 59: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Table 60: Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Integral Molecular Inc, H2 2019
List of Figures
Figure 1: Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
